Our study demonstrates that camrelizumab plus anlotinib may be a promising treatment option for patients with metastatic SCLC....PD-L1 were negative (Figure 7). Given the IHC results, the tumor was considered to conform to small cell carcinoma….we switched the treatment regimen to camrelizumab (200 mg, every three weeks) combined with anlotinib (10 mg, once daily, day 1–14, every three weeks)...contrast-enhanced abdominal CT showed that after 7 cycles of treatment with camrelizumab plus anlotinib, the multiple low-density nodules and masses in the mesenteric space had disappeared. No tumors were found in chest CT scan....Until November 2021, the survival time of the patient is 31 months. From the time of recurrence, the patient has survived for 23 months. From the time of two drugs used, he has survived for 19 months.